KALA News and Press, Kala Pharmaceuticals Inc. From 05/16/22

- Expanded Coverage for EYSUVIS® to 92% of Total Commercial Lives and 30% of All Medicare Lives - - Achieved 18% EYSUVIS Prescription Growth in 1Q 2022 - - Presented KPI-012 Phase 1b Clinical Data at ARVO; Initiation of Phase 2/3 Clinical Trial in PCED Expected 4Q 202...

Kala Pharmaceuticals (NASDAQ:KALA) is scheduled to announce Q1 earnings results on Monday, May 16th, before market open. The consensus EPS Estimate is -$0.29 and the consensus Revenue Estimate is $2.88M (-11.9% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revision and 0 down...

ARLINGTON, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report first qu...

Most people think of penny stocks as shares of companies trading for pennies. The standard definition considers these as stocks under $5, but you can’t argue with popular opinion. The exciting part about penny stocks under $1 is the volatility and gain potential they hold. Ca...

Kala Pharmaceuticals (NASDAQ:KALA) said that a large pharmacy benefit manager in the U.S. added dry eye disease therapy Eysuvis as a covered brand on its commercial formularies, effective May 1. The company said this adds 28.5M commercial lives to Eysuvis (loteprednol etabonate opht...

-- Now Covered by the largest Pharmacy Benefit Manager in the United States and Humana Medicare-- --Expands Commercial coverage to 92% of total commercial lives-- --Doubles Medicare coverage from 7.1 million lives to 14.1 million lives-- ARLINGTON, Mass., May 03, 2022 (G...

-- Data Demonstrate Rapid and Complete Wound Healing, with Six of Eight (75%) Patients Achieving Complete Healing within Four Weeks; All Remained Healed Through End of Follow-Up -- -- All Patients with Pain at Baseline Reported Zero Pain by Week 3 -- -- KPI-012 was Well-Tolera...

ARLINGTON, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will present data ...

JP Morgan has downgraded Kala Pharmaceuticals (NASDAQ:KALA) to underweight from neutral as the firm said that sales of the dry eye treatment Eysuvis (loteprednol etabonate) were below expectations. The firm cut its sales expectations in fiscal year 2022 for the eye drops as follows: Q1, $1.9M...

Kala Pharmaceuticals, Inc. (KALA) Q4 2021 Earnings Conference Call March 29, 2022 08:00 ET Company Participants Jill Steier - Executive Director, Investor Relations and Corporate Communications Mark Iwicki - Chairman and Chief Executive Officer Todd Bazemore - President and Chief Operating Of...